CHMP positive opinion is based on results from the Phase 3 SELECT-AXIS 2 study showing upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 response at week 14 versus placebo1 Non-radiographic… Read More
Fibrosis regression observed in 58% (7 of 12) of patients receiving 200 mg fazirsiran Median reduction of 83% of Z-AAT accumulation in the liver Reduction of 69% in histologic globule… Read More
VANCOUVER, BC – Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 from the 2022 ASCO General Meeting in metastatic colorectal cancer, one of the most difficult-to-treat… Read More
The pair will support leadership in the life sciences, biotech, and tech sectors. This is a partner message from Acetech. With a vision of supporting leadership within the life sciences,… Read More
UBC to expand physical therapy program to the heart of Surrey’s Health and Technology District SURREY, B.C. – Lark Group is pleased to welcome the University of British Columbia (UBC) to the Health and… Read More
